Prop. 65
This article was originally published in The Gray Sheet
Executive Summary
The state of California plans to appeal a recent U.S. district court ruling that FDA requirements for dental mercury preempt California's Proposition 65 warning requirements for the product. According to a appeal notice filed by California, the state's appeal brief -- which has not yet been filed -- will raise questions such as "whether the general [FDA] labeling requirements applicable to all medical devices and all prescription devices preempt the specific reproductive toxicity warning requirement imposed by Proposition 65." The district court concluded that preemption is legally necessary because California's rules are "different from, or in addition to" FDA's "specific requirements" for dental mercury. The state maintained that FDA's rules are not "specific requirements" but general controls that apply to all medical devices
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.